Northwestern Health Sciences University

Patient Experience Journal, published in association with The Beryl Institute, Releases Volume 10, Issue 3

Retrieved on: 
Tuesday, November 7, 2023
Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, Medical University of Vienna, Oregon Health & Science University, Ariel University, Research, Agility, University of California, San Francisco, University, Implementation research, Medical school, University of Alabama, Northwestern Health Sciences University, University of Michigan, Movement, Nursing, Management

NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire-PRWeb/ -- The Beryl Institute announces the publication of Volume 10, Issue 3 of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research and proven practices related to understanding and improving the patient experience. Read in over 220 countries and territories, PXJ articles have been downloaded over 1,100,000 times and reflect the journal's commitment to disseminating rigorous knowledge and expanding the global conversation on evidence and innovation in patient and human experience.

Key Points: 
  • "This issue closes the first decade of Patient Experience Journal's (PXJ) contribution to evidence and innovation, to sharing stories and research, to elevating the conversation and pushing the boundaries of the experience movement."
  • said Jason Wolf, Founding Editor of PXJ and President & CEO of The Beryl Institute.
  • "We have never hesitated to nudge at the status quo or to respond with agility to the challenging moments we have faced.
  • We have welcomed diverse voices as contributors, and we have seen an even more diverse readership."

Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis

Retrieved on: 
Monday, August 28, 2023
Retinoschisis, Medical school, Male, Oregon Health & Science University, RS1, Retina, Paratriathlon, Gene expression, AAV, Doctor of Philosophy, Oregon Health and Science University Center for Women's Health, MD, Patient, OHSU, School, Northwestern Health Sciences University, Medical genetics, Therapy, News, Safety, Pharmaceutical industry, Ophthalmology

DURHAM, N.C., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the first patient has been dosed in its Phase I/II clinical trial, the LIGHTHOUSE study, evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment.

Key Points: 
  • ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment.
  • “Dosing the first patient in the LIGHTHOUSE study marks a significant milestone for Atsena and the XLRS community,” said Kenji Fujita, MD, Chief Medical Officer of Atsena Therapeutics.
  • “We are excited to be utilizing AAV.SPR in the clinic, as it has the potential to revolutionize the treatment of XLRS, as well as other inherited retinal disorders.
  • Spreading laterally beyond the subretinal injection site, AAV.SPR facilitates the safe delivery of RS1 to photoreceptors in the central retina/fovea.

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity

Retrieved on: 
Thursday, June 22, 2023
Research, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, University, Therapy, Lancet Neurology, Phase II, Neurotoxicity, Efficacy, Immunoglobulin therapy, Clinical trial, Bone marrow, Oregon Health & Science University, NIH, Chapel Hill, DRS, University of South Florida, Myasthenia gravis, RNA, Autoimmunity, University of Miami, Bangladesh Technical Education Board, CAR, DSM-IV codes, National Institute of Neurological Disorders and Stroke, Cytokine release syndrome, MG, Patient, Physician, Northwestern Health Sciences University, Autotransplantation, NINDS, Paper, Toxic encephalopathy, American Neurological Association, Immunosuppression, Myasthenia, The Lancet, Lancet, Safety, Pharmaceutical industry, Vaccine, Stroke, Cartesian

Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

Key Points: 
  • Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.
  • The study describes Descartes-08, a cutting-edge RNA CAR-T (rCAR-T) therapy administered to patients with generalized myasthenia gravis (MG), a debilitating autoimmune neurological disease.
  • This is the first clinical trial using rCAR-T to treat autoimmunity, and the first successful Phase 2 trial using an engineered cell therapy to treat autoimmunity.
  • Clinical benefit was sustained long-term for most patients, even months after completing the course of therapy.

KLAS Research Emerging Technology Spotlight Report Indicates 100% Overall Satisfaction Score for CodaMetrix Customers

Retrieved on: 
Tuesday, April 18, 2023
University, Pathology, Oregon Health & Science University, KLAS, Radiology, HIMSS, Mass, Northwestern Health Sciences University, Mass General Brigham, AI, GI, Automation, Nursing

That is a high-volume area, so being able to cut back on overtime is huge," said one director from a leading academic health system.

Key Points: 
  • That is a high-volume area, so being able to cut back on overtime is huge," said one director from a leading academic health system.
  • "We had a large backlog sitting in a work queue waiting to be coded, and CodaMetrix's system has helped with that backlog.
  • "This report is tangible evidence of the value we create in leveraging AI and automation to transform healthcare revenue cycles for our clients."
  • For additional information, including access to the full KLAS report, visit https://www.codametrix.com/codametrix-klas-emerging-solutions/ or stop by the CodaMetrix booth at HIMSS (#8242)

Kibur Medical Presents a Rational Approach to Identify Novel Combinations as Potential Immuno-oncology Therapies at the American Academy of Cancer Research in Orlando, FL

Retrieved on: 
Thursday, April 6, 2023
Charles River Laboratories, AACR, Kidney cancer, CDX, Syngenic, GEMM, Annual International Exhibition, Booth, American Academy, Gordon Mills, PDX, Spatial analysis, Oregon Health Plan, Brigham, Drug combination, Northwestern Health Sciences University, Poster, Hospital, FDA, Tumor microenvironment, Oregon Health & Science University, Breast cancer, Pharmaceutical industry

BOSTON, April 6, 2023 /PRNewswire-PRWeb/ -- Kibur Medical Inc., a Boston, MA - based company with a vision to close the translational gap in next generation cancer therapies, will present two posters at the upcoming American Academy of Cancer Research (AACR) annual meeting in April describing immune-oncology applications of the Kibur technology. Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific combination therapies. The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in CDX, syngeneic, xenograft, GEMM & PDX tumor models.

Key Points: 
  • Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific combination therapies.
  • The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in CDX, syngeneic, xenograft, GEMM & PDX tumor models.
  • "This work furthers our mission to transform cancer care and advance precision medicine for better patient outcomes."
  • Following the AACR annual meeting, Kibur is both sponsoring and hosting panel sessions at the 4th Annual International Phase-0/Microdosing Stakeholder Meeting on April 24th in Boston.

Stork Club launches maternity program with clinical study showing significant reduction in preterm births and unnecessary C-sections

Retrieved on: 
Wednesday, March 22, 2023
Insurance, Stork Club, Medicaid, Pregnancy, Doula, Employment, Research, Blog, Person, Associate, IVF, CDC, Oregon Health Plan, Journal, JOEM, Journal of Occupational and Environmental Medicine, SAN, Child, Northwestern Health Sciences University, Disease, Mortality, BIPOC, Health, ROI, Apgar, Environmental medicine, Nightclub, Birth control

Stork Club is the first provider in the US to offer managed birth doula care under employer-sponsored health plans.

Key Points: 
  • Stork Club is the first provider in the US to offer managed birth doula care under employer-sponsored health plans.
  • Given their commitment to cost-effective, evidence-based care, Stork Club also announced the results of the study, currently under peer review in a leading academic journal, indicate that Stork Club doula care was associated with a 45% reduction in unnecessary c-sections and a 58% reduction in preterm births compared to national averages.
  • A study of Stork Club's program shows a substantial reduction in preterm births and unnecessary C-sections, resulting in lower overall maternity care costs.
  • Based on the study's results, birthing persons who used Stork Club Birth Doula care experienced 45% fewer Cesarean births and 58% fewer preterm births (vs.

Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences

Retrieved on: 
Tuesday, December 13, 2022
Baptist Health, Contessa, Translational Research Institute, Rehabilitation, Student, Palliative care, ROCK, Eating, Ageing, The Neurosciences Institute, Trauma, MBA, Investment, Arkansas Children's Hospital, Information, Modern Healthcare, Veterans Health Administration, Terrorism, Hospital, Home, Star, UAMS, QPC, Digital health, Level 1, Health, Winthrop, Lexington VA Medical Center, University of Arkansas for Medical Sciences, University, Patient, Hospice, Physician, Failure, Northwestern Health Sciences University, Government, Climate change, Anatomical pathology, The Last Best Place, Conditional sentence, Health care, Public health, Partnership, Medicine, Health insurance, Nursing, Pharmacy, Medicare, Central Arkansas, Amedisys

and NASHVILLE, Tenn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its joint venture with the University of Arkansas for Medical Sciences (UAMS) to provide home health services in Searcy and Little Rock.

Key Points: 
  • and NASHVILLE, Tenn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its joint venture with the University of Arkansas for Medical Sciences (UAMS) to provide home health services in Searcy and Little Rock.
  • This joint venture is part of the partnership between UAMS, Amedisys and Contessa, an Amedisys company, to offer patients a full spectrum of medical care in the comfort and convenience of their own homes through UAMS Health Comprehensive Care at Home.
  • Home health services will operate as UAMS Health Home Health across 12 counties in Central Arkansas.
  • Amedisys is the second largest provider of home health care and the third largest provider of hospice care in the United States.

Helius Medical Technologies, Inc. Announces Participation of Oregon Health & Science University in its Therapeutic Experience Program

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Forward-looking statement, Northwestern Health Sciences University, Center, Rehabilitation, Nasdaq, Research, Education, Health, Therapy, Private Securities Litigation Reform Act, Sale, Multiple sclerosis, Tongue, Pons, Neurology, International Classification of Functioning, Disability and Health, COVID-19, Traumatic brain injury, Helios, FAAN, MCR, Brain, News, Securities and Exchange Commission (Philippines), HSDT, Excellent, Gait, Time, Internet, Management of multiple sclerosis, Oregon Health & Science University, FANA, Company, Contract, Maintenance, Medicare, Patient, TEP, OHSU, MS, MD, Regulation, FDA, Pharmaceutical industry, Medical device, Medical imaging, Medicaid

NEWTOWN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced the addition of Oregon Health & Science University (OHSU) to its Therapeutic Experience Program (TEP).

Key Points: 
  • NEWTOWN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced the addition of Oregon Health & Science University (OHSU) to its Therapeutic Experience Program (TEP).
  • This initiative will be led by Vijayshree Yadav, MD, MCR, FANA, FAAN, Professor of Neurology and OHSU Multiple Sclerosis Center Director.
  • A significant portion of MS patients suffer from gait deficit and PoNS therapy provides a unique opportunity to improve gait functionality and mobility.
  • Oregon Health & Science University is Oregon's only academic health center and distinguished nationally as a research university dedicated solely to advancing health sciences.

University of Arkansas for Medical Sciences (UAMS) Announces a Partnership with Amedisys and Contessa, Creating a Comprehensive Care at Home Suite of Services

Retrieved on: 
Tuesday, October 11, 2022
NASDAQ, Institute, Arkansas Children's Hospital, University, Hospice, Lists of disasters, CEO, Trauma, Failure, UAMS, Terrorism, Winthrop, Manchester VA Medical Center, MBA, Digital health, Private Securities Litigation Reform Act, Company, Translational Research Institute, GLOBE, Level 1, Vision, Baptist Health, Government, Palliative care, Health, Ageing, Student, Rehabilitation, Eating, Physician, Veterans Health Administration, Caregiver, University of Arkansas for Medical Sciences, Public health, District, Patient, The Neurosciences Institute, Hospital, Home, Partnership, Contessa, Anatomical pathology, Adult, Northwestern Health Sciences University, COVID-19, Conditional sentence, Information, Healthcare, Health insurance, Management, Residential care, Risk management, Medicine, Central Arkansas, Nursing, Pharmacy, Amedisys, Medicare

LITTLE ROCK, Ark. and NASHVILLE, Tenn., Oct. 11, 2022 (GLOBE NEWSWIRE) -- The University of Arkansas for Medical Sciences (UAMS), Amedisys (NASDAQ: AMED), a leading health care at home company, and Contessa, an Amedisys company and the leading comprehensive care at home provider, announced a partnership bringing a new care at home option to Central Arkansas. The joint venture offers patients a full spectrum of medical care in the comfort and convenience of their own homes.

Key Points: 
  • We look forward to giving our patients an innovative option that delivers on our commitment of community-focused, patient-centered care.
  • UAMS Health Comprehensive Care at Home combines all the essential elements of primary, hospital or rehabilitation level care with the comfort of patients homes.
  • The service expands access across the continuum of care, increases critical inpatient capacity and reduces overall cost of care.
  • Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services.

Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022

Retrieved on: 
Wednesday, September 7, 2022
Acromegaly, SRL, Patient, ENEA, Degenerative disease, Neurosurgery, Northwestern Health Sciences University, Poster, Oregon Health & Science University, Physician, Union, RCT, Sequoyah, European, Adult, Oregon Health Plan, Lead, Congress, FACE, Capsule, Pharmaceutical industry, MD

Dr. Tracy Cunningham, Chief Medical Officer of Amryt,commented: These data provide important information for physicians when switching patients from injectable SRLs to Mycapssa.

Key Points: 
  • Dr. Tracy Cunningham, Chief Medical Officer of Amryt,commented: These data provide important information for physicians when switching patients from injectable SRLs to Mycapssa.
  • These patients were then followed for an additional nine months in the randomized controlled treatment (RCT) phase.
  • At the end of the RCT phase patients were provided the option to continue into an open label phase and receive Mycapssa.
  • Response was defined as the time-weighted average of IGF-1